KVD900 150 mg
KVD900-303
Phase 3 small_molecule completed
Quick answer
KVD900 150 mg for Hereditary Angioedema is a Phase 3 program (small_molecule) at KalVista Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- KalVista Pharmaceuticals
- Indication
- Hereditary Angioedema
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed